SEPN insider filings

Septerna, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen SEPN transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 6 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Ezekowitz Alan — Director1—7 legs · 81,820 sh · $3,934,363—
Labrucherie Gil M — Chief Financial Officer1—3 legs · 20,000 sh · $832,359—
Finer Jeffrey — Chief Executive Officer, Director1—5 legs · 18,500 sh · $807,0152
Bhatt Elizabeth — President and COO1—2 legs · 4,000 sh · $149,6442
Long Daniel D. — SVP, Drug Discovery1—1 leg · 3,333 sh · $126,0782
Patni Rajiv — Chief Medical Officer1——1

Recent insider filings — Septerna, Inc.

FiledFormInsiderReported transactionsSource
2026-11-184Labrucherie Gil M — Chief Financial OfficerSale (S): 15,815 @ $41.48 · Sale (S): 3,485 @ $41.99 · Sale (S): 700 @ $43EDGAR
2026-11-164Finer Jeffrey — Chief Executive Officer, DirectorOption exercise (M): 18,500 @ $2.76 · Sale (S): 5,600 @ $42.09 · Sale (S): 5,300 @ $43.10 · Sale (S): 2,800 @ $44.23 · Sale (S): 2,823 @ $45.28 · Sale (S): 1,977 @ $46.16 · +1 moreEDGAR
2026-11-134Ezekowitz Alan — DirectorSale (S): 6,939 @ $46.01 · Sale (S): 13,201 @ $47.01 · Sale (S): 22,865 @ $47.78 · Sale (S): 31,572 @ $48.70 · Sale (S): 4,175 @ $49.65 · Sale (S): 2,013 @ $50.90 · +1 moreEDGAR
2026-10-194Bhatt Elizabeth — President and COOOption exercise (M): 4,000 @ $6.81 · Sale (S): 1,094 @ $36.87 · Sale (S): 2,906 @ $37.61 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2026-09-104Patni Rajiv — Chief Medical OfficerGrant/award (A): 275,000 (derivative) @ $0EDGAR
2026-09-034Long Daniel D. — SVP, Drug DiscoveryOption exercise (M): 3,333 @ $2.76 · Sale (S): 3,333 @ $37.83 · Option exercise (M): 3,333 (derivative) @ $0EDGAR
2026-08-144Third Rock Ventures V, L.P. — 10% owner
Third Rock Ventures GP V, LP — 10% owner
TRV GP V, LLC — 10% owner
Third Rock Ventures VI, L.P. — 10% owner
Third Rock Ventures GP VI, L.P. — 10% owner
TRV GP VI, LLC — 10% owner
Sale (S): 147,059 @ $50.27 · Sale (S): 141 @ $51.08EDGAR
2026-08-144RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund III, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Sale (S): 746,500 @ $42.50 · Sale (S): 746,500 @ $42.50EDGAR
2026-08-134Bhatt Elizabeth — President and COOOption exercise (M): 18,681 @ $6.81 · Option exercise (M): 6,319 @ $2.76 · Sale (S): 25,000 @ $44 · Option exercise (M): 18,681 (derivative) @ $0 · Option exercise (M): 6,319 (derivative) @ $0EDGAR
2026-08-054Long Daniel D. — SVP, Drug DiscoveryOption exercise (M): 1,816 @ $2.76 · Option exercise (M): 1,518 @ $2.76 · Sale (S): 1,000 @ $33.98 · Sale (S): 2,334 @ $34.68 · Option exercise (M): 1,816 (derivative) @ $0 · Option exercise (M): 1,518 (derivative) @ $0EDGAR
2026-07-174Bhatt Elizabeth — President and COOOption exercise (M): 4,000 @ $6.81 · Sale (S): 4,000 @ $33.99 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2026-07-024Long Daniel D. — SVP, Drug DiscoveryOption exercise (M): 3,333 @ $2.76 · Sale (S): 2,100 @ $34.10 · Sale (S): 1,233 @ $34.81 · Option exercise (M): 3,333 (derivative) @ $0EDGAR
2026-06-304Shaikhly Samira — Chief People OfficerOption exercise (M): 2,178 @ $6.81 · Sale (S): 2,178 @ $35.18 · Option exercise (M): 2,178 (derivative) @ $0EDGAR
2026-06-304Bassan Abraham — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-304Simson Jake — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-304Coulie Bernard — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-304Ezekowitz Alan — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-304Gottesdiener Keith Michael — DirectorGrant/award (A): 11,260 (derivative) @ $0EDGAR
2026-06-304Tong Jeffrey K — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-304Sharp Shalini — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-304RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund III, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Grant/award (A): 15,000 (derivative) @ $0EDGAR
2026-06-244Long Daniel D. — SVP, Drug DiscoveryOption exercise (M): 10,529 @ $2.76 · Option exercise (M): 4,471 @ $11.70 · Sale (S): 8,000 @ $35.10 · Sale (S): 7,000 @ $35.97 · Option exercise (M): 10,529 (derivative) @ $0 · Option exercise (M): 4,471 (derivative) @ $0EDGAR
2026-06-164Shaikhly Samira — Chief People OfficerOption exercise (M): 6,250 @ $11.70 · Sale (S): 6,250 @ $35.08 · Option exercise (M): 6,250 (derivative) @ $0EDGAR
2026-06-034Shaikhly Samira — Chief People OfficerOption exercise (M): 4,355 @ $1.55 · Option exercise (M): 943 @ $2.76 · Option exercise (M): 637 @ $2.76 · Sale (S): 1,700 @ $27.78 · Sale (S): 1,346 @ $28.79 · Sale (S): 2,889 @ $29.66 · +3 moreEDGAR
2026-05-284Shaikhly Samira — Chief People OfficerOption exercise (M): 11,798 @ $6.81 · Sale (S): 11,798 @ $30.06 · Option exercise (M): 11,798 (derivative) @ $0EDGAR
2026-04-174Bhatt Elizabeth — President and COOOption exercise (M): 4,000 @ $6.81 · Sale (S): 2,573 @ $23.76 · Sale (S): 1,101 @ $25.24 · Sale (S): 326 @ $25.86 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2026-03-044Shaikhly Samira — Chief People OfficerOption exercise (M): 53,714 @ $1.55 · Option exercise (M): 11,638 @ $2.76 · Option exercise (M): 5,101 @ $2.76 · Sale (S): 4,090 @ $27.51 · Sale (S): 66,363 @ $28.14 · Option exercise (M): 53,714 (derivative) @ $0 · +2 moreEDGAR
2026-02-204Bhatt Elizabeth — President and COOOption exercise (M): 4,000 @ $6.81 · Sale (S): 2,200 @ $28.46 · Sale (S): 1,800 @ $29.58 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2026-02-104Long Daniel D. — SVP, Drug DiscoveryGrant/award (A): 80,000 (derivative) @ $0EDGAR
2026-02-104Klein Uwe — SVP, Biological SciencesGrant/award (A): 80,000 (derivative) @ $0EDGAR
2026-02-104Shaikhly Samira — Chief People OfficerGrant/award (A): 80,000 (derivative) @ $0EDGAR
2026-02-104Finer Jeffrey — Chief Executive Officer, DirectorGrant/award (A): 400,000 (derivative) @ $0EDGAR
2026-02-104Kim Jae B. — Chief Medical OfficerGrant/award (A): 125,000 (derivative) @ $0EDGAR
2026-02-104Wilson Mark Andrew — Chief Legal OfficerGrant/award (A): 165,000 (derivative) @ $0EDGAR
2026-02-104Bhatt Elizabeth — President and COOGrant/award (A): 155,000 (derivative) @ $0EDGAR
2026-02-104Labrucherie Gil M — Chief Financial OfficerGrant/award (A): 125,000 (derivative) @ $0EDGAR
2025-11-134Long Daniel D. — SVP, Drug DiscoverySale (S): 3,501 @ $18.06EDGAR
2025-09-294Gottesdiener Keith Michael — DirectorGrant/award (A): 33,246 (derivative) @ $0EDGAR
2025-08-194Klein Uwe — SVP, Biological SciencesOption exercise (M): 10,452 @ $2.76 · Option exercise (M): 4,935 @ $2.76 · Option exercise (M): 7,621 @ $6.81 · Option exercise (M): 10,452 (derivative) @ $0 · Option exercise (M): 4,935 (derivative) @ $0 · Option exercise (M): 7,621 (derivative) @ $0EDGAR
2025-08-114Shaikhly Samira — Chief People OfficerGrant/award (A): 30,000 (derivative) @ $0EDGAR
2025-08-114Finer Jeffrey — Chief Executive Officer, DirectorGrant/award (A): 210,000 (derivative) @ $0EDGAR
2025-08-114Long Daniel D. — SVP, Drug DiscoveryGrant/award (A): 30,000 (derivative) @ $0EDGAR
2025-08-114Klein Uwe — SVP, Biological SciencesGrant/award (A): 30,000 (derivative) @ $0EDGAR
2025-08-114Kim Jae B. — Chief Medical OfficerGrant/award (A): 55,000 (derivative) @ $0EDGAR
2025-08-114Bhatt Elizabeth — President and COOGrant/award (A): 95,000 (derivative) @ $0EDGAR
2025-08-114Labrucherie Gil M — Chief Financial OfficerGrant/award (A): 37,500 (derivative) @ $0EDGAR
2025-06-204Ezekowitz Alan — DirectorGrant/award (A): 16,623 (derivative) @ $0EDGAR
2025-06-204Tong Jeffrey K — DirectorGrant/award (A): 16,623 (derivative) @ $0EDGAR
2025-06-204Sharp Shalini — DirectorGrant/award (A): 16,623 (derivative) @ $0EDGAR
2025-06-204RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner
RA Capital Healthcare Fund LP — Director, 10% owner
RA Capital Nexus Fund III, L.P. — Director
Kolchinsky Peter — Director, 10% owner
Shah Rajeev M. — Director, 10% owner
Grant/award (A): 16,623 (derivative) @ $0EDGAR

Recent 8-K events — Septerna, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-048-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-258-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-308-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-138-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-098-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-028-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-128-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=SEPN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs